Archive · 10 Sep 2025
Indian Pharma Firms Adapt to Potential US Tariff Hikes
Imagine the US might make imported medicines more expensive.
This could be due to high tariffs, like a tax on the medicines.
Indian drug companies, who sell a lot of medicine to the US, are figuring out what to do.
They are thinking about selling more medicine in other places, like Europe or Africa, and also at home in India.
Some may start making medicines in the US, but that costs more.
They might also work with other companies to make parts of the medicines.
The goal is to keep medicine affordable for the US and keep Indian drug companies doing well.
US is considering tariffs of up to 250% on pharmaceutical imports.
Indian pharma firms are diversifying operations due to potential tariffs.
Companies are focusing on non-US markets and domestic market growth.
Indian generics account for 45% of US prescriptions.
Firms are exploring options like offshore manufacturing and contract manufacturing.
- Who
- Indian pharmaceutical companies
- What
- Are preparing for potential US tariffs on drug imports.
- When
- Following discussions in early August.
- Where
- In the US and India.
- Why
- Due to potential tariffs on pharmaceutical imports.
- Potential US Tariff Rate
- Up to 250%
- India's US Pharma Revenue Share
- About 35% or $10.7 billion
- Indian Generic Share of US Prescriptions
- 45%
- US Healthcare Savings (2022)
- $219 billion
- Savings from 2013-2022
- $1.3 trillion
- Projected US Savings (next 5 years)
- $1.3 trillion